Your browser doesn't support javascript.
loading
Dengue vaccines: progress and challenges.
Coller, Beth-Ann G; Clements, David E.
Affiliation
  • Coller BA; Vaccines Research, WP17-2131, Merck and Company, 770 Sumneytown Pike, P.O. Box 4, West Point, PA 19486, United States. beth-ann.coller@merck.com
Curr Opin Immunol ; 23(3): 391-8, 2011 Jun.
Article in En | MEDLINE | ID: mdl-21514129
ABSTRACT
With several dengue vaccine candidates progressing through clinical trials, several options for controlling this disease appear feasible. This would represent a major achievement and reflect decades of research and development activities. The challenges associated with the limited understanding of protective responses and those factors which determine disease severity remain, but with prospective studies ongoing in various dengue endemic areas and the initiation of dengue vaccine efficacy trials, immune responses are being evaluated in the context of protection and severe disease and these studies are highly likely to provide additional insights.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dengue / Dengue Vaccines Type of study: Observational_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Curr Opin Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2011 Document type: Article Affiliation country: United States Publication country: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dengue / Dengue Vaccines Type of study: Observational_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Curr Opin Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2011 Document type: Article Affiliation country: United States Publication country: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM